COMPARISON
Daptomycin vs Vancomycin
5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Daptomycin is authorised or registered in 10 and Vancomycin in 9 of the 10 registers read. Daptomycin: highest phase Phase 4 (after approval). Vancomycin: highest phase Phase 4 (after approval). 60 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Daptomycin | Vancomycin | |
|---|---|---|
| Registered trials differs | 132 clinicaltrials.gov · 2026-10-03 | 738 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Daptomycin openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Vancomycin Hydrochloride openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Authorised ema · 2026-10-03 | Nothing on record ema read 2026-08-31 |
| EU authorised on differs | 2006-01-19 ema · 2026-10-03 | Not checked no record of "authorisedOn" for vancomycin |
| ATC code differs | J01XX09 ema · 2026-10-03 | Not checked no record of "atcCode" for vancomycin |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Daptomycin | placebo | Vancomycin | placebo |
|---|---|---|---|---|
| Cough | - | - | 16.1% | 12.3% |
| Headache | - | - | 5.8% | 6.4% |
| Nausea | - | - | 5.0% | 5.3% |
| Pyrexia | - | - | 5.0% | 4.4% |
| Diarrhoea | - | - | 4.7% | 4.8% |
| Vomiting | - | - | 2.3% | 5.2% |
Trial register Daptomycin: 0 placebo-controlled trials; Vancomycin: 5. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Daptomycin side effects · Vancomycin side effects
LEGAL STATUS
Approval in each country read
| Country | Daptomycin | Vancomycin | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Not on the register | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
60 registered trials include both
| NCT00967941 | Vancomycin and Daptomycin Plus Cefazolin for Preoperative Vascular Surgery Prophylaxis COMPLETED · updated 2026-09-14 |
|---|---|
| NCT06637332 | Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia RECRUITING · updated 2026-09-09 |
| NCT07376889 | Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia RECRUITING · updated 2026-08-25 |
| 2024-514952-34-00 | Randomized open-label controlled trial evaluating a single-dose intravenous Dalbavancin versus standard antibiotic therapy during catheterrelated bloodstream in Not stated · updated 2026-07-30 |
| 2023-508442-18-00 | Efficacy and safety of different antimicrobial DURATions for the treatment of Infections associated with Osteosynthesis Material implanted after long bone fract Not stated · updated 2026-07-21 |
| 2026-526149-91-00 | Efficacy and safety of Dalbavancin in the treatment of infective Endocarditis caused by gram-positive cocci Not stated · updated 2026-06-30 |
| 2023-503582-35-00 | Staphylococcus aureus Network Adaptive Platform trial (SNAP) Not stated · updated 2026-05-06 |
| NCT05137119 | Staphylococcus Aureus Network Adaptive Platform Trial RECRUITING · updated 2026-05-06 |
| NCT05156437 | Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL) TERMINATED · updated 2026-05-05 |
| NCT04983901 | PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN COMPLETED · updated 2026-04-06 |
| 2024-516232-10-00 | Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study
to determine whether con Not stated · updated 2025-10-17 |
| NCT07148960 | Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? ENROLLING_BY_INVITATION · updated 2025-09-17 |
| NCT05977868 | Comparing Oral Versus Parenteral Antimicrobial Therapy TERMINATED · updated 2025-08-26 |
| 2023-508456-18-00 | Ramdomized non-inferiority clinical trial to evaluate the safety and efficacy of short duration therapy for non complicated enterococcal bacteremia. Not stated · updated 2025-08-08 |
| NCT07072923 | Antibiotic Impregnated Beads in Osteomyelitis NOT_YET_RECRUITING · updated 2025-07-18 |
| NCT05225558 | A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia TERMINATED · updated 2025-05-06 |
| NCT06959667 | Comparative Analysis of Nemonoxacin and Other Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA) Antimicrobial Therapy in Patients With Complicated Sk ACTIVE_NOT_RECRUITING · updated 2025-05-06 |
| NCT04775953 | DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia COMPLETED · updated 2024-12-10 |
| NCT01199783 | Application of Daptomycin in MRSA Infected Diabetic Foot in Comparison to Vancomycin Treatment TERMINATED · updated 2024-03-18 |
| NCT06189885 | Preoperative Daptomycin Prophylaxis in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded Trial UNKNOWN · updated 2024-01-05 |
The 20 most recently updated are listed.
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.